First approved by the Food and Drug Administration (FDA) in 2005 to treat type 2 diabetes, evenatide is sold under the trade names of Byetta (2x a day) and Bydureon (once weekly), taken by injection. The medication mimics incretin, a gastrointestinal hormone that stimulates the release of insulin following meals. This helps to lower blood sugar levels and prevents “spiking.” Biologically, it is similar to the body’s own GLP-1, which regulates glucose metabolism and insulin secretion. In the treatment of diabetes, evenatide is meant for people who are not able to control their blood sugar with oral medications alone. Byetta raises insulin levels quickly and lasts for 6-8 hours. Bydureon gives 24 hour coverage, but Byetta is better for leveling blood sugar spikes that occur after eating. To control high glucose levels which can lead to diabetes, Exenatide works in several ways. It helps insulin release directly in response to …